Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
Italy
· Delayed Price · Currency is EUR 53.80
+0.35 (0.65%)
Jun 27, 2025, 5:35 PM CET
Revenue by Product
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2012 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2012 - 2020 |
Specialty & Primary Care | 1.52B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Specialty & Primary Care Growth | 8.66% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Rare Diseases | 891.12M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Rare Diseases Growth | 20.82% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Pharmaceutical Chemicals | 60.16M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Pharmaceutical Chemicals Growth | 11.47% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Revenue seg2 | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Revenue seg2 Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Urology and Uro-Oncology | 405.90M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Urology and Uro-Oncology Growth | 28.55% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Cardiovascular | 392.76M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Cardiovascular Growth | 7.35% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Gastrointestinal | 224.74M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Gastrointestinal Growth | 2.38% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Cough and Cold | 127.68M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Cough and Cold Growth | -4.25% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Treatment Areas | 311.33M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Treatment Areas Growth | -0.47% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Endocrinology | 335.03M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Endocrinology Growth | 28.34% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Metabolic and Other Areas | 265.36M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Metabolic and Other Areas Growth | 0.10% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Oncology | 290.74M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Oncology Growth | 37.52% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Zanidip | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Zanidip Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Zanipress | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Zanipress Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Urorec | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Urorec Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Livazo | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Livazo Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Drugs for Rare Diseases | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Drugs for Rare Diseases Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Revenue seg3 | 2.35B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Revenue seg3 Growth | 12.89% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Seloken/Logimax | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Seloken/Logimax Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Corporate Products | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Corporate Products Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
OTC | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
OTC Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Local Product Portfolios | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Local Product Portfolios Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Product | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Product Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Eligard | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Eligard Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
EBIT by Product
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2012 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2012 - 2020 |
Specialty & Primary Care Operating Income | 423.81M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Specialty & Primary Care Operating Income Growth | 4.62% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Rare Diseases Operating Income | 223.91M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Rare Diseases Operating Income Growth | 33.89% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other EBIT seg1 | 57.73M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other EBIT seg1 Growth | -15.89% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
EBITDA by Product
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2012 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2012 - 2020 |
Specialty & Primary Care EBITDA | 523.35M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Specialty & Primary Care EBITDA Growth | 7.56% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Rare Diseases EBITDA | 368.53M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Rare Diseases EBITDA Growth | 20.30% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2012 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2012 - 2020 |
Italy Revenue | 340.63M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Italy Revenue Growth | 4.43% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
International Revenue | 2.07B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
International Revenue Growth | 14.37% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Europe Revenue | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Europe Revenue Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Asia and Oceania Revenue | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Asia and Oceania Revenue Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
America Revenue | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
America Revenue Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Africa Revenue | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Africa Revenue Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Specialty & Primary Care Like-For-Like Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Rare Diseases Like-For-Like Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Total Like-For-Like Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|